{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:52:58Z","timestamp":1790301178175,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Niemann-Pick Type C1 disorder (NPC) is a rare lysosomal storage disease characterized by the accumulation of cholesterol in lysosomes. NPC has no FDA approved treatments yet, however 2-hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD) has shown efficacy for treating the disease in both mouse and feline NPC models and is currently being investigated in late stage clinical trials. Despite promising results, therapeutic use of HP\u03b2CD is limited by the need for high doses, ototoxicity and intrathecal administration. These limitations can be attributed to its poor pharmacokinetic profile. In the attempt to overcome these limitations, we have designed a \u03b2-cyclodextrin (\u03b2CD) based polymer prodrugs (ORX-301) for an enhanced pharmacokinetic and biodistribution profile, which in turn can potentially provide an improved efficacy at lower doses. We demonstrated that subcutaneously injected ORX-301 extended the mean lifespan of NPC mice at a dosage 5-fold lower (800\u2009mg\/kg, body weight) the HP\u03b2CD dose proven efficacious (4000\u2009mg\/kg). We also show that ORX-301 penetrates the blood brain barrier and counteracts neurological impairment. These properties represent a substantial improvement and appear to overcome major limitations of presently available \u03b2CD-based therapy, demonstrating that\u00a0this novel prodrug is\u00a0a valuable alternative\/complement for existing therapies.<\/jats:p>","DOI":"10.1038\/s41598-018-27926-9","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:10:26Z","timestamp":1529320226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0444-5974","authenticated-orcid":false,"given":"Aditya","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Dolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniya","family":"Johny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Dragotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Macone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Fiorenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"27926_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.277.5323.228","volume":"277","author":"ED Carstea","year":"1997","unstructured":"Carstea, E. D. et al. Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol Homeostasis. Science 277, 228\u2013231 (1997).","journal-title":"Science"},{"key":"27926_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1034\/j.1399-0004.2003.00147.x","volume":"64","author":"MT Vanier","year":"2003","unstructured":"Vanier, M. T. & Millat, G. Niemann-Pick disease Type C. Clin. Genet. 64, 269\u2013281 (2003).","journal-title":"Clin. Genet."},{"key":"27926_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier, M. T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"27926_CR4","doi-asserted-by":"publisher","first-page":"12391","DOI":"10.1073\/pnas.221181998","volume":"98","author":"Y Sugimoto","year":"2001","unstructured":"Sugimoto, Y. et al. Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann-Pick C1-deficient cells. Proc. Natl. Acad. Sci. 98, 12391\u201312396 (2001).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"27926_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ymgme.2009.06.009","volume":"98","author":"JE Wraith","year":"2009","unstructured":"Wraith, J. E. et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol. Genet. Metab. 98, 250\u2013254 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"27926_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbalip.2004.08.011","volume":"1685","author":"SU Walkley","year":"2004","unstructured":"Walkley, S. U. & Suzuki, K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 1685, 48\u201362 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"27926_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-013-0164-6","volume":"74","author":"KA Lyseng-Williamson","year":"2014","unstructured":"Lyseng-Williamson, K. A. Miglustat: a review in its use in Niemann-Pick disease type C. Drugs 74, 61\u201374 (2014).","journal-title":"Drugs"},{"key":"27926_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith, J. E. et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol. Genet. Metab. 99, 351\u2013357 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"27926_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ymgme.2009.11.007","volume":"99","author":"M Pineda","year":"2010","unstructured":"Pineda, M. et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol. Genet. Metab. 99, 358\u2013366 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"27926_CR10","doi-asserted-by":"publisher","first-page":"335ra118","DOI":"10.1126\/scitranslmed.aad9823","volume":"8","author":"T Kirkegaard","year":"2016","unstructured":"Kirkegaard, T. et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci. Transl. Med. 8, 335ra118 (2016).","journal-title":"Sci. Transl. Med."},{"key":"27926_CR11","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","volume":"58","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz, A. J. & Horowitz, S. M. Targeting histone deacetylase in T-cell lymphoma. Leuk. Lymphoma 58, 1306\u20131319 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"27926_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s13311-013-0217-2","volume":"10","author":"P Helquist","year":"2013","unstructured":"Helquist, P., Maxfield, F. R., Wiech, N. L. & Wiest, O. Treatment of Niemann-Pick Type C disease by histone deacetylase inhibitors. Neurotherapeutics. 10, 688\u2013697 (2013).","journal-title":"Neurotherapeutics."},{"key":"27926_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0169-409X(98)00092-1","volume":"36","author":"L Szente","year":"1999","unstructured":"Szente, L. & Szejtli, J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 36, 17\u201328 (1999).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"27926_CR14","doi-asserted-by":"publisher","first-page":"17250","DOI":"10.1074\/jbc.270.29.17250","volume":"270","author":"EPC Kilsdonk","year":"1995","unstructured":"Kilsdonk, E. P. C. et al. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270, 17250\u201317256 (1995).","journal-title":"J. Biol. Chem."},{"key":"27926_CR15","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.1074\/jbc.M111.326405","volume":"287","author":"KB Peake","year":"2012","unstructured":"Peake, K. B. & Vance, J. E. Normalization of cholesterol homeostasis by 2-hydroxypropyl-\u00df-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice. J. Biol. Chem. 287, 9290\u20139298 (2012).","journal-title":"J. Biol. Chem."},{"key":"27926_CR16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/1440-1681.12285","volume":"41","author":"AM Lopez","year":"2014","unstructured":"Lopez, A. M. et al. Systemic administration of 2-hydroxypropyl-\u03b2-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin Exp Pharmacol Physiol. 41, 780\u2013787 (2014).","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"27926_CR17","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1194\/jlr.M028241","volume":"53","author":"AM Taylor","year":"2012","unstructured":"Taylor, A. M. et al. Cyclodextrin mediates rapid changes in lipid balance in Npc1-\/- mice without carrying cholesterol through the bloodstream. J Lipid Res. 53, 2331\u20132342 (2012).","journal-title":"J Lipid Res."},{"key":"27926_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/acn3.306","volume":"3","author":"CD Davidson","year":"2016","unstructured":"Davidson, C. D. et al. Efficacy and ototoxicity of different cyclodextrins in Niemann-Pick C disease. Ann. Clin. Trans. Neurol. 3, 366\u2013380 (2016).","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"27926_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0024-3205(01)01384-4","volume":"70","author":"F Camargo","year":"2001","unstructured":"Camargo, F. et al. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 70, 131\u2013142 (2001).","journal-title":"Life Sci."},{"key":"27926_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1203\/PDR.0b013e3181ee4dd2","volume":"68","author":"CM Ramirez","year":"2010","unstructured":"Ramirez, C. M. et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res. 68, 309\u2013315 (2010).","journal-title":"Pediatr. Res."},{"key":"27926_CR21","doi-asserted-by":"publisher","first-page":"e6951","DOI":"10.1371\/journal.pone.0006951","volume":"4","author":"CD Davidson","year":"2009","unstructured":"Davidson, C. D. et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. Plos One 4, e6951 (2009).","journal-title":"Plos One"},{"key":"27926_CR22","doi-asserted-by":"publisher","first-page":"276ra26","DOI":"10.1126\/scitranslmed.3010101","volume":"7","author":"CH Vite","year":"2015","unstructured":"Vite, C. H. et al. Intracisternal 2-hydroxypropyl-\u03b2-cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Sci. Transl. Med. 7, 276ra26 (2015).","journal-title":"Sci. Transl. Med."},{"key":"27926_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymgme.2015.07.001","volume":"116","author":"TJ Maarup","year":"2015","unstructured":"Maarup, T. J. et al. Intrathecal 2-hydroxypropyl-\u03b2-cyclodextrin in a single patient with Niemann-Pick C1. Mol. Genet. Metab. 116, 75\u201379 (2015).","journal-title":"Mol. Genet. Metab."},{"key":"27926_CR24","first-page":"31465","volume":"17","author":"DS Ory","year":"2017","unstructured":"Ory, D. S. et al. Intrathecal 2-hydroxypropyl-\u03b2-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 17, 31465\u20134 (2017).","journal-title":"Lancet"},{"key":"27926_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10545-012-9583-x","volume":"36","author":"CC Pontikis","year":"2013","unstructured":"Pontikis, C. C. et al. Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability. J Inherit Metab Dis. 36, 491\u2013498 (2013).","journal-title":"J Inherit Metab Dis."},{"key":"27926_CR26","doi-asserted-by":"publisher","first-page":"e53280","DOI":"10.1371\/journal.pone.0053280","volume":"7","author":"MA Crumling","year":"2012","unstructured":"Crumling, M. A. et al. Hearing loss and hair cell death in mice given the cholesterol-chelating agent hydroxypropyl-\u03b2-cyclodextrin. PLoS One 7, e53280 (2012).","journal-title":"PLoS One"},{"key":"27926_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1203\/PDR.0b013e3181df4623","volume":"68","author":"S Ward","year":"2010","unstructured":"Ward, S., O\u2019Donnell, P., Fernandez, S. & Vite, C. H. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res. 68, 52\u201356 (2010).","journal-title":"Pediatr Res."},{"key":"27926_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1023\/A:1015929720063","volume":"7","author":"HW Frijlink","year":"1990","unstructured":"Frijlink, H. W. et al. The pharmacokinetics of \u03b2-cyclodextrin and 2-hydroxypropyl-\u03b2-cyclodextrin in the rat. Pharm. Res. 7, 1248\u20131252 (1990).","journal-title":"Pharm. Res."},{"key":"27926_CR29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1248\/bpb.b14-00726","volume":"38","author":"Y Tanaka","year":"2015","unstructured":"Tanaka, Y. et al. Efficacy of 2-hydroxypropyl-\u03b2-cyclodextrin in Niemann-Pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease. Biol. Pharm. Bull. 38, 844\u2013851 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"27926_CR30","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1021\/bi3010889","volume":"52","author":"CJ Collins","year":"2013","unstructured":"Collins, C. J. et al. Synthesis, characterization, and evaluation of pluronic-based \u03b2-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick Type C fibroblasts. Biochemistry. 52, 3242\u20133253 (2013).","journal-title":"Biochemistry."},{"key":"27926_CR31","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1021\/bm400922a","volume":"14","author":"YA Mondjinou","year":"2013","unstructured":"Mondjinou, Y. A. et al. Synthesis of 2-hydroxypropyl-\u03b2-cyclodextrin\/Pluronic-based polyrotaxanes via heterogeneous reaction as potential Niemann-Pick Type C therapeutics. Biomacromolecules. 14, 4189\u20134197 (2013).","journal-title":"Biomacromolecules."},{"key":"27926_CR32","volume":"12","author":"A Tamura","year":"2014","unstructured":"Tamura, A. & Yui, N. Lysosomal-specific cholesterol reduction by biocleavable polyrotaxanes for ameliorating Niemann-Pick type C disease. Sci Rep. 12, 4356 (2014).","journal-title":"Sci Rep."},{"key":"27926_CR33","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.1074\/jbc.M115.636803","volume":"290","author":"A Tamura","year":"2015","unstructured":"Tamura, A. & Yui, N. \u03b2-Cyclodextrin-threaded biocleavable polyrotaxanes ameliorate impaired autophagic flux in Niemann-Pick type C disease. J Biol Chem. 290, 9442\u20139454 (2015).","journal-title":"J Biol Chem."},{"key":"27926_CR34","doi-asserted-by":"publisher","first-page":"326ra23","DOI":"10.1126\/scitranslmed.aad9407","volume":"8","author":"MS Alam","year":"2016","unstructured":"Alam, M. S., Getz, M. & Haldar, K. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Sci Transl Med. 8, 326ra23 (2016).","journal-title":"Sci Transl Med."},{"key":"27926_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep31750","volume":"6","author":"A Brown","year":"2016","unstructured":"Brown, A. et al. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick type C1 disease-based lysosomal storage disorder. Sci Rep. 6, 31750 (2016).","journal-title":"Sci Rep."},{"key":"27926_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep46737","volume":"7","author":"CJ Collins","year":"2017","unstructured":"Collins, C. J. et al. Pluronic based \u03b2-Cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease. Sci Rep. 7, 46737 (2017).","journal-title":"Sci Rep."},{"key":"27926_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/bc060259s","volume":"18","author":"S Lee","year":"2007","unstructured":"Lee, S. et al. Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug Chem. 18, 4\u20137 (2007).","journal-title":"Bioconjug Chem."},{"key":"27926_CR38","doi-asserted-by":"publisher","first-page":"15956","DOI":"10.1039\/C5CC05242D","volume":"51","author":"S Maity","year":"2015","unstructured":"Maity, S. et al. A biodegradable adamantane polymer with ketal linkages in its backbone for gene therapy. Chem Commun (Camb). 51, 15956\u201315959 (2015).","journal-title":"Chem Commun (Camb)."},{"key":"27926_CR39","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1194\/jlr.M000257","volume":"51","author":"B Liu","year":"2010","unstructured":"Liu, B. et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid. J. Lipid Res. 51, 933\u2013944 (2010).","journal-title":"J. Lipid Res."},{"key":"27926_CR40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/hmg\/ddr505","volume":"21","author":"RA Maue","year":"2012","unstructured":"Maue, R. A. et al. A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Hum Mol Genet. 21, 730\u2013750 (2012).","journal-title":"Hum Mol Genet."},{"key":"27926_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1073\/pnas.94.4.1488","volume":"94","author":"MS Airaksinen","year":"1997","unstructured":"Airaksinen, M. S. et al. Ataxia and altered dendritic calcium signaling in mice carrying a targeted null mutation of the calbindin D28k gene. Proc Natl Acad Sci USA 94, 1488\u20131493 (1997).","journal-title":"Proc Natl Acad Sci USA"},{"key":"27926_CR42","doi-asserted-by":"crossref","unstructured":"Davis, M. E. & Brewster, M. E. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 3, 1023\u20131035.","DOI":"10.1038\/nrd1576"},{"key":"27926_CR43","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.addr.2009.05.005","volume":"61","author":"ME Davis","year":"2009","unstructured":"Davis, M. E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev. 61, 1189\u20131192 (2009).","journal-title":"Adv Drug Deliv Rev."},{"key":"27926_CR44","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.drudis.2015.05.008","volume":"20","author":"V Bonnet","year":"2015","unstructured":"Bonnet, V. et al. Cyclodextrin nanoassemblies: a promising tool for drug delivery. Drug Discov Today. 20, 1120\u20131126 (2015).","journal-title":"Drug Discov Today."},{"key":"27926_CR45","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1039\/C0CS00019A","volume":"40","author":"C Ortiz Mellet","year":"2011","unstructured":"Ortiz Mellet, C., Garc\u00eda Fern\u00e1ndez, J. M. & Benito, J. M. Cyclodextrin-based gene delivery systems. Chem Soc Rev. 40, 1586\u20131608 (2011).","journal-title":"Chem Soc Rev."},{"key":"27926_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/1568026613666131127160118","volume":"14","author":"EA Ottinger","year":"2014","unstructured":"Ottinger, E. A. et al. Collaborative development of 2-hydroxypropyl-\u00df-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr. Top. Med. Chem. 14, 330\u2013339 (2014).","journal-title":"Curr. Top. Med. Chem."},{"key":"27926_CR47","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1021\/acsnano.5b01285","volume":"9","author":"J Agudo-Canalejo","year":"2015","unstructured":"Agudo-Canalejo, J. & Lipowsky, R. Critical Particle Sizes for the Engulfment of Nanoparticles by Membranes and Vesicles with Bilayer Asymmetry. ACS Nano 9, 3704\u20133720 (2015).","journal-title":"ACS Nano"},{"key":"27926_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.nbd.2014.06.012","volume":"70","author":"S Nusca","year":"2014","unstructured":"Nusca, S. et al. A marked paucity of granule cells in the developing cerebellum of the Npc1(\u2212\/\u2212) mouse is corrected by a single injection of hydroxypropyl-\u03b2-cyclodextrin. Neurobiol Dis. 70, 117\u2013126 (2014).","journal-title":"Neurobiol Dis."},{"key":"27926_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40478-016-0370-z","volume":"4","author":"P Caporali","year":"2016","unstructured":"Caporali, P. et al. Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis. Acta Neuropathol Commun. 4, 94 (2016).","journal-title":"Acta Neuropathol Commun."},{"key":"27926_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott, N. J., Patabendige, A. A., Dolman, D. E., Yusof, S. R. & Begley, D. J. Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13\u201325 (2010).","journal-title":"Neurobiol Dis"},{"key":"27926_CR51","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.1021\/ja00328a047","volume":"106","author":"I Tabushi","year":"1984","unstructured":"Tabushi, I. & Kuroda, Y. Bis(histamino)cyclodextrin-Zn-Imidazole Complex as an Artificial Carbonic Anhydrase. J. Am. Chem. Soc. 106, 4580\u20134584 (1984).","journal-title":"J. Am. Chem. Soc."},{"key":"27926_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12311-010-0211-8","volume":"11","author":"S Canterini","year":"2012","unstructured":"Canterini, S. et al. Subcellular TSC22D4 Localization in Cerebellum Granule Neurons of the Mouse Depends on Development and Differentiation. Cerebellum 11, 28\u201340 (2012).","journal-title":"Cerebellum"},{"key":"27926_CR53","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1093\/hmg\/ddu331","volume":"23","author":"B Tortelli","year":"2014","unstructured":"Tortelli, B. et al. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). Hum. Mol. Genet. 23, 6022\u20136033 (2014).","journal-title":"Hum. Mol. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27926-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27926-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T06:33:29Z","timestamp":1671604409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-27926-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["27926"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-27926-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"5 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9547"}}